

Title (en)  
PHARMACEUTICAL COMPOSITIONS COMPRISING PARACETAMOL AND PROCESS FOR PREPARING THE SAME

Title (de)  
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT PARACETAMOL UND HERSTELLUNGSVERFAHREN DAFÜR

Title (fr)  
COMPOSITIONS PHARMACEUTIQUES CONTENANT DU PARACÉTAMOL ET PROCÉDÉ POUR LES PRÉPARER

Publication  
**EP 2588097 B1 20210224 (EN)**

Application  
**EP 11746019 A 20110629**

Priority  
• IN 630MU2010 A 20100909  
• IN 3023MU2009 A 20100630  
• IB 2011001519 W 20110629

Abstract (en)  
[origin: WO2012001494A2] Disclosed herein are injectable compositions containing high concentration of paracetamol or its pharmaceutically acceptable salts wherein the concentration of paracetamol or its pharmaceutically acceptable salt is >150mg/ml in a judiciously tailored solvent system comprising glycofurol, ethanol, water or a solvent system comprising glycofurol, ethanol, polyethylene glycol, water. The viscosity of the said injectables is <28 cps. Further disclosed is the process for preparing the said injectables. The injectables can be administered by intramuscular route, intravenous route or as intravenous infusion after diluting in one of the routinely used intravenous fluids, infusion solutions of antibacterial, antifungal and amoebicidal drugs and along with anxiolytics (Midazolam injection ) or narcotic analgesics (Fentanyl Citrate injection etc) as they remain stable, clear and transparent atleast for 6 hours after dilution.

IPC 8 full level  
**A61K 31/167** (2006.01); **A61K 9/00** (2006.01); **A61K 9/08** (2006.01); **A61K 47/10** (2017.01); **A61K 47/22** (2006.01)

CPC (source: EP KR US)  
**A61K 9/0019** (2013.01 - EP US); **A61K 9/08** (2013.01 - KR); **A61K 31/167** (2013.01 - EP KR US); **A61K 47/02** (2013.01 - US); **A61K 47/10** (2013.01 - KR US); **A61K 47/22** (2013.01 - EP KR US); **A61P 25/00** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 29/00** (2017.12 - EP)

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2012001494 A2 20120105; WO 2012001494 A3 20120518**; AP 2012006645 A0 20121231; AP 3932 A 20161216; AR 083154 A1 20130206; AU 2011273064 B2 20140109; BR 112012031928 A2 20170620; BR 112012031928 B1 20210831; CA 2802303 A1 20120105; CA 2802303 C 20160614; CN 102958519 A 20130306; CN 102958519 B 20160113; CO 6592023 A2 20130102; CU 20120178 A7 20130327; DK 2588097 T3 20210510; EA 023022 B1 20160429; EA 201291433 A1 20130530; EP 2588097 A2 20130508; EP 2588097 B1 20210224; ES 2866636 T3 20211019; HU E054171 T2 20210830; IL 222780 A0 20121231; IL 222780 A 20170831; JP 2013529675 A 20130722; JP 5872551 B2 20160301; KR 101587942 B1 20160122; KR 20130100243 A 20130910; MX 2012014800 A 20130129; MY 156469 A 20160226; PE 20130782 A1 20130620; PE 20170426 A1 20170412; PL 2588097 T3 20210906; PT 2588097 T 20210525; TW 201206420 A 20120216; TW I538673 B 20160621; UA 109544 C2 20150910; US 2013096201 A1 20130418; US 9616128 B2 20170411; ZA 201209674 B 20130925

DOCDB simple family (application)  
**IB 2011001519 W 20110629**; AP 2012006645 A 20110629; AR P110102305 A 20110630; AU 2011273064 A 20110629; BR 112012031928 A 20110629; CA 2802303 A 20110629; CN 201180029973 A 20110629; CO 12222733 A 20121207; CU 20120178 A 20121227; DK 11746019 T 20110629; EA 201291433 A 20110629; EP 11746019 A 20110629; ES 11746019 T 20110629; HU E11746019 A 20110629; IL 22278012 A 20121031; JP 2013517570 A 20110629; KR 20127032943 A 20110629; MX 2012014800 A 20110629; MY PI2012004793 A 20110629; PE 2012002483 A 20110629; PE 2017000257 A 20110629; PL 11746019 T 20110629; PT 11746019 T 20110629; TW 100123159 A 20110630; UA A201213891 A 20110629; US 201113806541 A 20110629; ZA 201209674 A 20121220